培美曲塞或吉西他滨联合顺铂治疗晚期非小细胞肺癌的比较研究

目的比较培美曲塞或吉西他滨联合顺铂治疗晚期非小细胞肺癌(NSCLC)的疗效及不良反应。方法选择晚期NSCLC患者50例,随机分为培美曲塞加顺铂组(PC组)和吉西他滨加顺铂组(GC组)各25例。PC组给予培美曲塞500mg/m2,第1天,GC组吉西他滨1000mg/m2,第1、8天,两组均给予顺铂30mg,第2～4天,均为21d一个周期。结果培美曲塞加顺铂组和吉西他滨加顺铂组有效率分别为48%和44%,两组之间有效率无统计学意义(P>0.05)。PC组粒细胞减少的发生率小于GC组。结论 PC方案治疗晚期非小细胞肺癌的疗效与GC方案的疗效相当,但毒副作用明显减少,可以作为一线治疗方案。

Efficacy and Toxicity of Pemetrexed or Gemcitabine plus Cisplatin in Treatment of Patients with Non-small Cell Lung Cancer

Objective To observe the efficacy and toxicity of pemetrexed or gemcitabine plus cisplatin in treatment of patients with non-small cell lung cancer（NSCLC）.Methods 50 patients with late stage NSCLC were enrolled into this study.These patients were divided into PC（pemetrexed plus cisplatin） group （n=25） and GC （gemcitabine plus cisplatin）group （n=25） （PC： pemetrexed 500mg/m2 plus cisplatin 30mg/m2, GC：gemcitabine 1000mg/m2 plus cisplatin 30mg/m2）.The efficacy of patients received two or more cycles will be evaluated.Results Altogether 50 patients were evaluated. The effective rate in PC groups was 48% and in GC group was 44%. The common side effects were gastrolntestinal toxins and hematologic toxicities including nausea, neutrocytopenia,and anemia, but they were rarer in PC group. Conclusions Pemetrexed plus cisplatin had the same activity as gemcitabine plus cisplatin in treatment of patients with NSCLC,and they appeared to be more-tolerated.